



Republic of the Philippines  
DEPARTMENT OF HEALTH  
OFFICE OF THE SECRETARY

21 January 2015

**CERTIFICATION**


This is to certify the provisional exemption for one year, effective upon receipt of this certificate, of the following medicine:

Medicine: **Pegylated Liposomal Doxorubicin hydrochloride 2mg/mL Solution for Injection**

Indication: For the treatment of metastatic breast cancer.

The product shall only be utilized by the requesting party – the Armed Forces of the Philippines Medical Center, and the concerned proponent shall provide to the Formulary Executive Council (FEC) through the National Center for Pharmaceutical Access and Management (NCPAM) the following: (1) local safety profile; (2) surveillance report on adverse effects; and (3) impact study/outcomes of patients using the product. These shall be submitted after expiration of the validity.

For compliance and strict implementation.

  
ANNA MELISSA S. GUERRERO, MD, MPH (HTA)  
OIC, Program Manager  
National Center for Pharmaceutical Access and Management

P N F X - 2 0 1 5 - 0 0 2